Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
Andrea Henden(The University of Queensland), Corey Smith(QIMR Berghofer Medical Research Institute), K. Lineburg(Chulalongkorn University), Edward Wright(Chulalongkorn University), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Laëtitia Le Texier(QIMR Berghofer Medical Research Institute), Pauline Crooks(QIMR Berghofer Medical Research Institute), J. Raju, Siok‐Keen Tey(The University of Queensland)
Cited by 0
Related Papers
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
|Proceedings of the National Academy of Sciences|2004|440
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
|The Journal of Experimental Medicine|1992|391
Antibody–Drug Conjugates for Cancer Therapy
|Molecules|2020|377
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
|Proceedings of the National Academy of Sciences|1999|332
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.
|The Journal of Experimental Medicine|1994|276